en · de · es
cardarine-notes.peptides1004.com › Topic › Detection, Stability, And Quality — Complete Guide

Detection, Stability, And Quality — Complete Guide

By Editorial Desk · published 2026-02-16 · last reviewed 2026-03-12 · Topic

A practical reference on PPARδ agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2026-03-12 and is reviewed periodically as new material appears.

Detection, Stability, and Quality

Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.

Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.

Regulatory Status and Detection Context

Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.

Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.

A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.

Cardarine at a glance

PropertyValueNotes
AppearanceWhite to off-white powderCommon for reference-grade material.
SolubilityLow in waterDissolves in DMSO and some organic solvents.
Typical storage-20 °C, desiccatedProtect from light and moisture.
Analytical methodLC-MS/MSUsed for trace detection in biological matrices.
Purity assessmentHPLC with UV detectionOften combined with NMR and mass spectrometry.

Preclinical Findings and Safety Signals

Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.

Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.

Related pages on this site

Detection, Regulation, and Quality Context

Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.

Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.

Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.

Identity and Regulatory Status

Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.

Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.

Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.

Further detail

United States The new 323 arrived in the United States for the 1986 model year and continued to be available through 1989. The naming practice was now aligned with most of Mazda's export markets, with the 323 badge replacing GLC. For 1987 the wagon version was added to the lineup, with the same mechanicals as the hatchbacks and saloons. In 1988, Mazda added a turbocharged option in the GT and GTX model as well as four-wheel drive in the GTX model. The GTX was the first four-wheel drive passenger car Mazda offered in the United States. The GT and GTX featured a turbocharged and intercooled 1.6 liter 16-valve DOHC 4-cylinder engine rated at 132 hp (98 kW) and only was available with a 5-speed manual transmission.

Seizures Delay in development Cardiac issues Swallowing difficulty Neurological problems Fukuyama congenital muscular dystrophy also affects the nervous system and various associated parts. FCMD affects normal development of the brain producing a broadly smooth, bumpy shaped cortex named cobblestone lissencephaly as well as various other malformations, notably micropolygyria. Children also experience delayed myelination in the brain.

== Applications == Differential scanning calorimetry can be used to measure a number of characteristic properties of a sample. Using this technique it is possible to observe fusion and crystallization events as well as glass transition temperatures Tg. DSC can also be used to study oxidation, as well as other chemical reactions. Glass transitions may occur as the temperature of an amorphous solid is increased. These transitions appear as a step in the baseline of the recorded DSC signal. This is due to the sample undergoing a change in heat capacity; no formal phase change occurs. As the temperature increases, an amorphous solid will become less viscous. At some point the molecules may obtain enough freedom of motion to spontaneously arrange themselves into a crystalline form. This is known as the crystallization temperature (Tc). This transition from amorphous solid to crystalline solid is an exothermic process, and results in a peak in the DSC signal. As the temperature increases the sample eventually reaches its melting temperature (Tm). The melting process results in an endothermic peak in the DSC curve. The ability to determine transition temperatures and enthalpies makes DSC a valuable tool in producing phase diagrams for various chemical systems. Differential scanning calorimetry can also be used to obtain valuable thermodynamics information about proteins. The thermodynamics analysis of proteins can reveal important information about the global structure of proteins, and protein/ligand interaction.

Sources: en.wikipedia.org

Background from the literature

Phytoestrogens exert their effects primarily through binding to estrogen receptors (ER). There are two variants of the estrogen receptor, alpha (ER-α) and beta (ER-β) and many phytoestrogens display somewhat higher affinity for ER-β compared to ER-α. The key structural elements that enable phytoestrogens to bind with high affinity to estrogen receptors and display estradiol-like effects are:

== Zirconium-88 == 88Zr is a radioisotope of zirconium with a half-life of 83.4 days. In January 2019, this isotope was discovered to have a thermal neutron capture cross section of approximately 861,000 barns; this is several orders of magnitude greater than predicted, and greater than that of any other nuclide except xenon-135.

The inaugural Foundation scholar was nobel laureate Linus Pauling and the Foundation has brought many other eminent research chemists to Australia. The Foundation has thus functioned to increase Australian awareness of state of the art international research, increased international recognition of Australian research, and allowed graduate students to interact with leading chemists based in institutions far from Australia. Many of the students have gone on to post-graduate or post-doctoral positions with a Foundation scholar. Freeman also provided advice to the Australian Government on the problem of access to "big science" facilities. This included making major contributions to the report Small Country - Big Science in his work for the Australian Science and Technology Council. The report emphasised the need for Australian researchers to have access to facilities such as synchrotron X-ray and high intensity neutron sources, and led directly to the formation of the Australian Synchrotron Research Programme (ASRP) to fund access to such facilities. Freeman served as a board member of the ASRP until its functions were subsumed under the newly commissioned Australian Synchrotron in 2008. The Australian expertise developed as a consequence of ASRP-supported research led to the Australian Synchrotron being built a decade sooner than would have otherwise been the case. Freeman retired from his Chair in 1997, and was succeeded by Len Lindoy FAA.

The company divides its international operations into three segments; the Middle East, Europe and Africa division (EMEA), Asia-Pacific (APAC) and Latin America and the Caribbean (LAC). In each of these regions, Burger King has established several subsidiaries to develop strategic partnerships and alliances to expand into new territories. In its EMEA group, Burger King's Switzerland-based subsidiary Burger King Europe GmbH is responsible for the licensing and development of BK franchises in those regions. In APAC region, the Singapore-based BK AsiaPac, Pte. Ltd. business unit handles franchising for East Asia, the Asian subcontinent and all Oceanic territories. The LAC region includes Mexico, Central and South America and the Caribbean Islands and has no centralized operations group.

Sources: en.wikipedia.org

Reference notes

=== Supplements === The use of certain amino acids may slow muscle breakdown by providing the body with the building blocks needed for metabolism of muscle and glucose. Specifically, leucine and valine may block muscle breakdown. Glutamine is used in oral supplements for people with advanced cancer or HIV/AIDS. β-hydroxy β-methylbutyrate (HMB) is a molecule that comes from leucine that promotes muscle growth. Studies show positive results for chronic pulmonary disease, hip fracture, and in AIDS-related and cancer-related cachexia. However, it is often studied along with other nutrients, making it difficult to assess its effects alone. Creatine supplementation may help reduce muscle wasting, though more research is needed.

=== Other uses and similar symbols === The main attribute of Vishnu is a wheel like weapon called the Sudarśanacakra. Similar wheel symbols were used as a solar symbol by the Ancient Egyptians. Some Buddha statues also depict the related Dharmachakra Mudrā, a hand sign depicting the turning of the Dharma wheel. A very similar wheel symbol also appears in the flag of the Romani people, hinting to their nomadic history. In non-Buddhist cultural contexts, an eight-spoked wheel resembles a traditional ship's wheel. As a nautical emblem, this image is a common sailor tattoo, which may be misidentified as a dharmachakra or vice versa. The sonnenrad is a similar symbol used by occultists and neo-nazis. Falun Gong uses the concept of a similar wheel as a central concept. In the Unicode computer standard, the dharmachakra is called the "Wheel of Dharma" and found in the eight-spoked form. It is represented as U+2638 (☸). As emoji: ☸️.

=== Role of cysteinyl leukotrienes === Cysteinyl leukotriene receptors CYSLTR1 and CYSLTR2 are present on mast cells, eosinophil, and endothelial cells. During cysteinyl leukotriene interaction, they can stimulate proinflammatory activities such as endothelial cell adherence and chemokine production by mast cells. As well as mediating inflammation, they induce asthma and other inflammatory disorders, thereby reducing the airflow to the alveoli. The levels of cysteinyl leukotrienes, along with 8-isoprostane, have been reported to be increased in the EBC of patients with asthma, correlating with disease severity. Cysteinyl leukotrienes may also play a role in adverse drug reactions in general and in contrast medium induced adverse reactions in particular. In excess, the cysteinyl leukotrienes can induce anaphylactic shock.

Sources: en.wikipedia.org

Frequently asked questions

How is cardarine measured in biological samples?

LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.

What storage conditions are typical for reference material?

Reference material is usually kept cold, dry, and protected from light. Frozen aliquots reduce repeated freeze-thaw cycles.

Why can purity vary between products?

No approved pharmaceutical product exists, so manufacturing and quality controls are not standardized. Products may contain different compounds or impurities.

Is cardarine approved for any medical use?

No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.

Network